Richard Depersio, MD
Plastic Surgery within the Head & Neck · Powell, TNNPI 1457435794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations.
Across 120 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$585
- Sanofi$537
- GSK$389
- Optinose US, Inc.$266
- Merck$114
- Stryker$110
- plus $506 from 17 others
What the payments were for
- Food & beverage$2,26890%
- Education$24010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 23 | $585 |
| Sanofi | 26 | $537 |
| GSK | 20 | $389 |
| Optinose US, Inc. | 14 | $266 |
| Merck | 6 | $114 |
| Stryker | 5 | $110 |
| Genentech USA, Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Intersect ENT, Inc. | 3 | $53 |
| Acera Surgical, Inc. | 2 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $32 |
| Boston Scientific | 2 | $30 |
| Baxter Healthcare | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $20 |
| Covidien LP | 1 | $18 |
| Acclarent, Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Endogastric Solutions, Inc | 1 | $15 |
| Novartis | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
Too few plastic surgery within the head & neck providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 192 | $7,282 |
| Azelastine Hcl | 155 | $3,922 |
| Cevimeline Hcl | 25 | $2,982 |
| Fluticasone Propionate | 162 | $2,332 |
| Ipratropium Bromide | 58 | $1,713 |
| Alprazolam | 575 | $1,594 |
| Mometasone Furoate | 54 | $929 |
| Meclizine Hcl | 80 | $593 |
| Triamcinolone Acetonide | 17 | $471 |
| Montelukast Sodium | 37 | $426 |
| Cephalexin | 41 | $424 |
| Doxycycline Hyclate | 49 | $320 |
| Mupirocin | 42 | $311 |
| Omeprazole | 11 | $277 |
| Diazepam | 167 | $274 |
Paid to pharmacies, not to this prescriber.
Other plastic surgery within the head & neck in Powell
- Jason HallKnoxville$68K
- James ShireChattanooga$33K
- Eben RosenthalNashville$23K
- James BekenyNashville$10K
- Elizabeth PerkinsNashville$9K
- Howard HammerDickson$7K
- Marc FeeleyNashville$3K
- Samuel SmithMemphis$2K
- Charles SewallOak Ridge$2K
- Jacqueline BoothOak Ridge$792
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.